The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The agreement could rise to $900 million if key commercial milestones are met
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
On the generics and biosimilars front, the combined business is expected to benefit from Sun’s portfolio of more than 550 approved ANDAs across multiple dosage forms
In his new role, Gregory will drive partnerships for the company’s large-scale molecule biologics business across Europe
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
Subscribe To Our Newsletter & Stay Updated
